Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bioprojet currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is being examined by a distinct examiner, CHANDRAKUMAR, NIZAL S. As the busiest examiner for the company, CHANDRAKUMAR, NIZAL S is responsible for 1 pending office action, which constitutes the entire active workload for the portfolio. The prosecution is concentrated in a distinct art unit, suggesting a specific focus within the Biotechnology & Pharmaceuticals sector.
For a practitioner, this means that the company's current patent efforts are tied to the specific examination style of a single individual. With only a distinct examiner and a distinct art unit involved, there is no internal baseline for comparing examiner behavior within this portfolio. The 1 pending office action represents the critical path for the company's current intellectual property goals, requiring a strategy tailored specifically to the expectations of the assigned examiner. This focused profile indicates that the company's immediate success in the Biotechnology & Pharmaceuticals area depends on this 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18849569 | NOVEL USE OF PITOLISANT FOR TREATING SEVERE FATIGUE | CHANDRAKUMAR, NIZAL S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18849569 | NOVEL USE OF PITOLISANT FOR TREATING SEVERE FATIGUE | CHANDRAKUMAR, NIZAL S | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18849569 | NOVEL USE OF PITOLISANT FOR TREATING SEVERE FATIGUE | CHANDRAKUMAR, NIZAL S | 1625 | §103§112Other | Non-Final OA | — | Pending | Sep 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBioprojet has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nizal S Chandrakumar has the most, with 1 of Bioprojet's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
